Additionally, the PD-L1 tumor population had an increase in median OS time (11 months vs. 9.4 months), as well as an increase in both six-month (80.2% vs. 75.2%) and 12-month (47.3% vs. 41.4%) estimated OS compared to the PD-L1-negative tumor population receiving pembrolizumab therapy [37]. Here, CD274 is linked to neoplasm.